ODTX (59) PRME (21) MGTX (27) GLUE (33) ⌘ Pro Terminal →

Cullinan Therapeutics Inc. (CGEM) — RQD Stock Rating Cockpit

$15.45 -0.71% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Cullinan Therapeutics Inc. (CGEM) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $994.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CGEM)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

45.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE53% OF RANGE

L: $7$15.45H: $23

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CGEM

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and -17.68% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (32)

11/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like CGEM

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CGEM)

✓Walkthrough of CGEM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CGEM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.39%📐 HORIZONTAL RANGE

2026-10-30O $15.38H $15.72L $14.70C $15.45VOL 389.4K

RES: $27.31SUP: $12.32SMA50: $17.91SMA200: $15.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CGEM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CGEM Butterfly Map → + Track CGEM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CGEM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CGEM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CGEM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CGEM)

Health Care Rank #775 of 1016 ⚔️ ODTX vs CGEM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CGEM vs. ODTX, PRME, MGTX, GLUE)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cullinan Therapeutics Inc. (CGEM) ranks #775 by composite RQD confidence (36/100, grade D-) and #362 by equity capitalization ($994.3M). Within this direct 5-issuer industry benchmark cohort, CGEM leads on earnings valuation at N/A trailing P/E, while CGEM leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with CGEM at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CGEM ACTIVE Cullinan Therapeutics Inc.	D-	36/100	—	—	-35.0%	-0.71%	$994.3M	Benchmark Subject
ODTX Odyssey Therapeutics Inc.	C-	59/100	—	—	—	+1.48%	$953.0M	/odtx-vs-cgem →
PRME Prime Medicine Inc.	E	21/100	—	—	-35.0%	-2.24%	$950.4M	/prme-vs-cgem →
MGTX MeiraGTx Holdings plc	E	27/100	—	—	-35.0%	-0.46%	$932.1M	/mgtx-vs-cgem →
GLUE Monte Rosa Therapeutics Inc.	E	33/100	—	—	-35.0%	+0.18%	$927.4M	/glue-vs-cgem →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001789972

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cullinan Therapeutics Inc. (CGEM) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$219.9M, operating cash flow of -$175.8M, and free cash flow of -$175.8M (-21.0% YoY). On the balance sheet, CGEM closed FY2025 with $448.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$219.9M	-$175.8M	-$175.8M	$448.4M	—
FY2024 (FY)	2024-12-31	$0	-$167.6M	-$145.3M	-$145.3M	$621.8M	—
FY2023 (FY)	2023-12-31	$0	-$155.1M	-$134.3M	-$134.3M	—	—

3. CGEM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CGEM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cullinan Therapeutics Inc. (NASDAQ: CGEM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $15.45 (-0.71% 1D, market cap $994.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CGEM ranks #775 in composite RQD confidence.

How does CGEM compare to ODTX and PRME in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ODTX (Odyssey Therapeutics Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $953.0M) and PRME (Prime Medicine Inc.) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M). Among the 5-stock peer group, CGEM leads on earnings multiple (N/A) while CGEM leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CGEM?

Per CGEM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001789972), Cullinan Therapeutics Inc. generated $0 in revenue, -$219.9M in net income, and -$175.8M in free cash flow against $448.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CGEM trading relative to its 50-day, 200-day, and 52-week technical levels?

CGEM last traded at $15.45 (-0.71% on volume of 460,099 shares), positioning the stock -13.74% below its 50-day simple moving average ($17.91) and -2.28% below its 200-day simple moving average ($15.81). Across its 52-week range of $6.73 to $23.19, CGEM sits at the 53.0% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.52 to $17.38).

CGEM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CGEM stock right now?

Cullinan Therapeutics Inc. (CGEM) currently earns a Roarable Rating of D- (Sell — SELL) with 36/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is CGEM's 12-month price target and RQD AI Jury consensus?

CGEM's 12-month base price target is $13.92 (range $10.86 to $24.35), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CGEM RQD Cockpit CGEM 12M Forecast CGEM Earnings & Move CGEM Dividends & DRIP CGEM Insiders & 13F CGEM Whale Options CGEM Profit Sankey CGEM News & Why